CHAMPIONS ONCOLOGY, INC. Comprehensive Income
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Comprehensive Income of -$13.14 million for the 12-month period ending 2015-04-30, per its 10-K filed 2015-07-29.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2015-07-29
- CHAMPIONS ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2015-04-30 was -$3.68M.
- CHAMPIONS ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2015-01-31 was -$2.82M.
- CHAMPIONS ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2014-10-31 was -$3.08M.
- CHAMPIONS ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2014-07-31 was -$3.55M.
- CHAMPIONS ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2015 was -$13.14M.
- CHAMPIONS ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2014 was -$7.31M.
- CHAMPIONS ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2013 was -$6.30M.
- CHAMPIONS ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2012 was -$8.72M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2015-04-30 | -$3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-29 | -$6.49M derived: sum of 2 quarters · filed 2015-07-29 | -$9.57M derived: sum of 3 quarters · filed 2015-07-29 | -$13.14M 10-K · filed 2015-07-29 | |
| 2015-01-31 | -$2.82M 10-Q · filed 2015-03-17 | -$5.89M derived: sum of 2 quarters · filed 2015-03-17 | -$9.46M 10-Q · filed 2015-03-17 | -$11.59M derived: sum of 4 quarters · filed 2015-07-29 | |
| 2014-10-31 | -$3.08M 10-Q · filed 2014-12-15 | -$6.68M 10-Q · filed 2014-12-15 | -$8.78M derived: sum of 3 quarters · filed 2015-07-29 | -$9.35M derived: sum of 4 quarters · filed 2015-07-29 | |
| 2014-07-31 | -$3.55M 10-Q · filed 2014-09-12 | -$5.70M derived: sum of 2 quarters · filed 2015-07-29 | -$6.27M derived: sum of 3 quarters · filed 2015-07-29 | -$8.60M derived: sum of 4 quarters · filed 2015-07-29 | |
| 2014-04-30 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-29 | -$2.72M derived: sum of 2 quarters · filed 2015-07-29 | -$5.05M derived: sum of 3 quarters · filed 2015-07-29 | -$7.31M 10-K · filed 2015-07-29 | |
| 2014-01-31 | -$573.00K 10-Q · filed 2015-03-17 | -$2.90M derived: sum of 2 quarters · filed 2015-03-17 | -$5.16M 10-Q · filed 2015-03-17 | -$7.19M derived: sum of 4 quarters · filed 2015-03-17 | |
| 2013-10-31 | -$2.33M 10-Q · filed 2014-12-15 | -$4.58M 10-Q · filed 2014-12-15 | -$6.62M derived: sum of 3 quarters · filed 2014-12-15 | -$7.61M derived: sum of 4 quarters · filed 2014-12-15 | |
| 2013-07-31 | -$2.24M 10-Q · filed 2014-09-12 | -$2.24M 10-Q · filed 2013-09-13 | -$4.29M derived: sum of 2 quarters · filed 2014-09-12 | -$5.28M derived: sum of 3 quarters · filed 2014-09-12 | -$7.25M derived: sum of 4 quarters · filed 2014-09-12 |
| 2013-04-30 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-07-28 | -$3.03M derived: sum of 2 quarters · filed 2014-07-28 | -$5.01M derived: sum of 3 quarters · filed 2014-07-28 | -$6.30M 10-K · filed 2014-07-28 | |
| 2013-01-31 | -$989.00K 10-Q · filed 2014-03-14 | -$2.96M derived: sum of 2 quarters · filed 2014-03-14 | -$4.26M 10-Q · filed 2014-03-14 | -$6.87M derived: sum of 4 quarters · filed 2014-03-14 | |
| 2012-10-31 | -$1.97M 10-Q · filed 2013-12-13 | -$3.27M 10-Q · filed 2013-12-13 | -$5.88M derived: sum of 3 quarters · filed 2013-12-13 | -$7.61M derived: sum of 4 quarters · filed 2013-12-13 | |
| 2012-07-31 | -$1.30M 10-Q · filed 2013-09-13 | -$3.91M derived: sum of 2 quarters · filed 2013-09-13 | -$5.64M derived: sum of 3 quarters · filed 2013-09-13 | -$7.98M derived: sum of 4 quarters · filed 2013-09-13 | |
| 2012-04-30 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2013-07-26 | -$4.34M derived: sum of 2 quarters · filed 2013-07-26 | -$6.68M derived: sum of 3 quarters · filed 2013-07-26 | -$8.72M 10-K · filed 2013-07-26 | |
| 2012-01-31 | -$1.73M 10-Q · filed 2013-03-13 | -$4.07M derived: sum of 2 quarters · filed 2013-03-13 | -$6.11M 10-Q · filed 2013-03-13 | -$8.89M derived: sum of 4 quarters · filed 2013-03-13 | |
| 2011-10-31 | -$2.34M 10-Q · filed 2012-12-13 | -$4.37M 10-Q · filed 2012-12-13 | -$7.16M derived: sum of 3 quarters · filed 2012-12-13 | -$7.57M derived: sum of 4 quarters · filed 2012-12-13 | |
| 2011-07-31 | -$2.03M 10-Q · filed 2012-09-12 | -$4.82M derived: sum of 2 quarters · filed 2012-09-12 | -$5.22M derived: sum of 3 quarters · filed 2012-09-12 | -$5.30M derived: sum of 4 quarters · filed 2012-09-12 | |
| 2011-04-30 | -$2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2012-07-18 | -$3.19M derived: sum of 2 quarters · filed 2012-07-18 | -$3.27M derived: sum of 3 quarters · filed 2012-07-18 | -$3.87M 10-K · filed 2012-07-18 | |
| 2011-01-31 | -$403.00K 10-Q · filed 2012-03-14 | -$479.00K derived: sum of 2 quarters · filed 2012-03-14 | -$1.07M 10-Q · filed 2012-03-14 | ||
| 2010-10-31 | -$76.00K 10-Q · filed 2011-12-14 | -$671.00K 10-Q · filed 2011-12-14 | |||
| 2010-07-31 | -$587.00K 10-Q · filed 2011-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |